Sigilon Therapeutics, Inc. Common Stock

SGTX

Capitalización de mercado USD 56.5 M

Acerca de: Sigilon Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is developing a new class of therapeutics and functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. Its lead product candidate, SIG-001, prevents bleeding in patients with moderate-severe to severe Hemophilia A.

Empleados: 62